BC Week In Review | May 2, 2016
Clinical News

Enstilar calcipotriene/betamethasone dipropionate aerosol foam regulatory update

The U.K. approved Leo’s Enstilar calcipotriene/ betamethasone foam spray to treat plaque psoriasis in adults. In March, Leo said Enstilar received a positive outcome under EU’s decentralized procedure (see BioCentury, April 11). The aerosol foam...
BioCentury | Oct 30, 2006

Connetics chronicles

Connetics chronicles Connetics (CNCT), which last week agreed to be acquired by Stiefel for about $640 million in cash, has seen two big stock runs abruptly cut short when setbacks prompted investors to bail out...
BC Week In Review | Jul 24, 2006
Clinical News

Betamethasone Foam: Phase I/II data

In an Israeli Phase I/II trial in 30 patients comparing Foamix's Betamethasone foam with Betnovate cream, both compounds significantly improved psoriatic plaques versus baseline. The compounds were applied to different plaques on each patient, and...
BC Extra | Mar 18, 2005
Financial News

Connetics raises $150M in note deal

CNCT raised $150 million in a bumped-up placing of convertible senior notes. The notes mature in 2015, bear 2% interest and convert into stock at $35.46, a 35% premium to CNCT's Thursday close of $26.27....
BioCentury | Mar 8, 1999

Choppy waters

Small waves of optimism and pessimism are roiling the waters as another life science company stepped up to sell an IPO, while two NASDAQ IPOs have been put on ice, including cancer vaccine play Intracel...
Items per page:
1 - 5 of 5